Sciwind Biosciences Published T2DM Phase III EECOH-2 Trial Results of Ecnoglutide in Lancet Diabetes & Endocrinology

Hangzhou, China & San Francisco, U.S. – Aug 23, 2025 — Sciwind Biosciences, a clinical-stage biotech company focusing on metabolic diseases, today announced Phase III EECOH-2 trial results evaluating ecnoglutide injection (XW003) in Chinese adults with type 2 diabetes mellitus (T2DM) inadequately controlled by metformin. The findings, published in The Lancet Diabetes & Endocrinology (IF: 41.8), show that ecnoglutide injection, the first global cAMP-biased GLP-1 receptor agonist, demonstrated favorable glucose-lowering efficacy and comprehensive benefits in cardiovascular and metabolic risk factors.

Professor Xiaoying Li from Zhongshan Hospital Affiliated to Fudan University is the corresponding author of this paper, and Dr Yang He from Zhongshan Hospital Affiliated to Fudan University is the first author. In addition, Feifei Jiang from Sciwind Biosciences serves as co-corresponding author.

The EECOH-2 trial was a multicenter, randomized, open-label, active-controlled (dulaglutide 1.5mg) Phase III trial conducted across 52 sites in China. Adults with a diagnosis of type 2 diabetes, and elevated glucose concentrations on metformin monotherapy were included. Participants were randomly assigned (1:1:1) to receive subcutaneous ecnoglutide injection (0.6 mg or 1.2 mg) or dulaglutide injection (1.5 mg) once weekly for 52 weeks.

Results showed that the reduction of HbA1c at week 32, which is the primary endpoint, was greater in both ecnoglutide dose groups compared to the dulaglutide 1.5 mg group, with the ecnoglutide groups achieving a mean HbA1c reduction up to 1.91% from baseline. At week 52, the proportions of participants achieving HbA1c <7.0% and HbA1c ≤6.5% were significantly higher in the ecnoglutide 0.6 mg and 1.2 mg groups than the dulaglutide 1.5 mg group. Both doses of ecnoglutide resulted in significantly greater blood glucose reduction compared to dulaglutide 1.5 mg, with higher proportions of participants achieving glycemic targets.

Compared with dulaglutide 1.5 mg, ecnoglutide significantly improved fasting plasma glucose, 2-hour post-prandial glucose, body weight, waist circumference, hip circumference, triglycerides and BMI, indicating comprehensive metabolic benefits.

Ecnoglutide showed a safety profile similar to that of approved GLP-1 receptor agonists. The most common adverse events were mild-to-moderate gastrointestinal disorders and decreased appetite, which occurred primarily in the dose-escalation period and subsided within a short duration. Discontinuation rates due to adverse events were low; no severe hypoglycemia events were reported.

“China has approximately 140 million adult patients with type 2 diabetes, ranking first in the world. Disease management is particularly complex due to frequent comorbidities such as overweight/obesity and cardiovascular diseases, creating an urgent need for a new generation of highly effective and safe innovative drugs to change the landscape. “Said Dr. Xiaoying Li, Principal Investigator of the EECOH-2 trial. “The publication of the EECOH-2 study marks that ecnoglutide has made significant progress in the field of type 2 diabetes treatment. The study confirms that, in metformin-inadequately controlled adults, ecnoglutide exhibits superior glycemic efficacy and comprehensive metabolic benefits. Notably, both ecnoglutide groups achieved greater HbA1c reduction than the dulaglutide 1.5mg group, and the proportions of participants achieving HbA1c <7.0% and HbA1c ≤6.5% were also significantly higher than in the dulaglutide 1.5 mg group. Its unique mechanism as a cAMP-biased GLP-1 receptor agonist enhances glycemic control and also has advantages in improving metabolic risk factors such as body weight reduction. The incidence of adverse events leading to study discontinuation or study drug withdrawal was low. The overall safety profile was consistent with the GLP-1 RA class , and no new safety signals were detected. Ecnoglutide injection provides Chinese diabetic patients a more accessible, effective, and safe treatment option.”

“The recent publications of the EECOH-2 and SLIMMER phase III clinical studies in The Lancet Diabetes & Endocrinology, a top journal in the diabetes and endocrinology, highlight the important milestones for ecnoglutide injection, the first global cAMP-biased GLP-1 receptor agonist. The New Drug Applications of ecnoglutide injection for both treatment of type 2 diabetes and weight management in overweight/obese patients were accepted by China’s NMPA in 2024. Sciwind Biosciences remains dedicated to advancing this innovative treatment to the patients in need, aiming to benefit individuals affected by diabetes, obesity, and other related metabolic conditions.” Said Dr. Hai Pan, the Founder and CEO of Sciwind Biosciences.

Investor and Media Resources

About Ecnoglutide

Ecnoglutide injection, originally discovered and developed by Sciwind Biosciences, is the first global, long-acting cAMP-biased GLP-1 receptor agonist enhancing biological efficacy and sustainability. Ecnoglutide injection has successfully completed three Phase III clinical trials, supporting Marketing Authorization Applications in China for treatment of adults with type 2 diabetes, as well as adults with obesity or overweight. From Phase I through Phase III, ecnoglutide injection has consistently demonstrated a favorable safety profile and strong efficacy, underscoring its potential as a promising therapy for patients with metabolic diseases.

About EECOH-2 and the Ecnoglutide Clinical Development Program

The EECOH-2 trial represents a pivotal component of Sciwind's comprehensive clinical development program for ecnoglutide, which has totally enrolled over 2,000 participants across multiple clinical trials in metabolic diseases in China and Australia. EECOH-2 delivers robust, evidence-based validation of ecnoglutide as the first global cAMP-biased GLP-1 therapy, confirming its efficacy and safety in adults with type 2 diabetes inadequately controlled by metformin.

About Sciwind Biosciences

Sciwind Biosciences is a clinical-stage biotech company focusing on discovering and developing innovative therapies to treat metabolic diseases. Sciwind has established a robust pipeline anchored by the lead asset, ecnoglutide (XW003), currently in the NDA stage in China. It has developed multiple proprietary technology platforms, including biased agonist discovery platform, long-acting and oral peptide delivery platforms, and has identified a series of drug candidates based on these core technology platforms. Sciwind has built an extensive pipeline targeting GLP-1 and synergistic pathways, offering both injectable and oral treatment solutions to deliver sustainable and high-quality therapies for patients with metabolic diseases.

For more information, please visit www.sciwindbio.com. 

Contacts

General Information: PR@sciwindbio.com

Business Development: BD@sciwindbio.com